In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focus On The Core: Merck Claims R&D Restructuring Poised To Produce Results

Executive Summary

At an R&D day presentation in Boston, Merck executives claimed R&D restructuring is beginning to bear fruit, presenting the pharma with a host of near-term launch possibilities. Outside of cancer immunotherapy, Merck has obtained or anticipates approvals in cardiovascular health, insomnia, diabetes, hepatitis C, osteoporosis, and allergies.

You may also be interested in...



Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself

Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.

Merck Bets Big On Oncology In New R&D Strategy

The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.

IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher

New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel